Terms: = Prostate cancer AND ETV1, DKFZp781L0674, 2115, ENSG00000006468, ER81, MGC120533, MGC104699, MGC120534 AND Treatment
23 results:
1. Development and characterization of an etv1 rabbit monoclonal antibody for the immunohistochemical detection of etv1 expression in cancer tissue specimens.
Schafer C; Young D; Singh H; Jayakrishnan R; Banerjee S; Song Y; Dobi A; Petrovics G; Srivastava S; Srivastava S; Sesterhenn IA; Chesnut GT; Tan SH
J Immunol Methods; 2023 Jul; 518():113493. PubMed ID: 37196930
[TBL] [Abstract] [Full Text] [Related]
2. Phase II Trial of Imatinib Plus Binimetinib in Patients With treatment-Naive Advanced Gastrointestinal Stromal Tumor.
Chi P; Qin LX; Nguyen B; Kelly CM; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Movva S; Nacev BA; Rosenbaum E; Thornton KA; Crago AM; Yoon S; Ulaner G; Yeh R; Martindale M; Phelan HT; Biniakewitz MD; Warda S; Lee CJ; Berger MF; Schultz ND; Singer S; Hwang S; Chen Y; Antonescu CR; Tap WD
J Clin Oncol; 2022 Mar; 40(9):997-1008. PubMed ID: 35041493
[TBL] [Abstract] [Full Text] [Related]
3. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
Bicak M; Lückerath K; Kalidindi T; Phelps ME; Strand SE; Morris MJ; Radu CG; Damoiseaux R; Peltola MT; Peekhaus N; Ho A; Veach D; Malmborg Hager AC; Larson SM; Lilja H; McDevitt MR; Klein RJ; Ulmert D
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15172-15181. PubMed ID: 32532924
[TBL] [Abstract] [Full Text] [Related]
4. Oncogenic ETS Factors in prostate cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract] [Full Text] [Related]
5. A novel PTPRZ1-etv1 fusion in gliomas.
Matjašič A; Zupan A; Boštjančič E; Pižem J; Popović M; Kolenc D
Brain Pathol; 2020 Mar; 30(2):226-234. PubMed ID: 31381204
[TBL] [Abstract] [Full Text] [Related]
6. Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.
Eich ML; Chandrashekar DS; Rodriguez Pen A MDC; Robinson AD; Siddiqui J; Daignault-Newton S; Chakravarthi BVSK; Kunju LP; Netto GJ; Varambally S
Prostate; 2019 Oct; 79(14):1629-1639. PubMed ID: 31376196
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of outcomes of radiotherapy-treated localized prostate cancer patients within a clinical trial setting versus real-life setting.
Abdel-Rahman O
Future Oncol; 2019 Apr; 15(11):1269-1277. PubMed ID: 30887820
[TBL] [Abstract] [Full Text] [Related]
8. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on prostate cancer.
Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
[No Abstract] [Full Text] [Related]
9. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
Liu CY; Yu T; Huang Y; Cui L; Hong W
J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
[TBL] [Abstract] [Full Text] [Related]
10. The role of miR-24 as a race related genetic factor in prostate cancer.
Hashimoto Y; Shiina M; Kato T; Yamamura S; Tanaka Y; Majid S; Saini S; Shahryari V; Kulkarni P; Dasgupta P; Mitsui Y; Sumida M; Deng G; Tabatabai L; Kumar D; Dahiya R
Oncotarget; 2017 Mar; 8(10):16581-16593. PubMed ID: 28157714
[TBL] [Abstract] [Full Text] [Related]
11. Influence of demographic and tumour variables on prostate cancer treatment with curative intent in Spain. Results of the 2010 national prostate cancer registry.
Martínez-Jabaloyas JM; Castelló-Porcar A; González-Baena AC; Cózar-Olmo JM; Miñana-López B; Gómez-Veiga F; Rodriguez-Antolín A;
Actas Urol Esp; 2016 Oct; 40(8):485-91. PubMed ID: 27260350
[TBL] [Abstract] [Full Text] [Related]
12. Development of Castration Resistant prostate cancer can be Predicted by a DNA Hypermethylation Profile.
Angulo JC; Andrés G; Ashour N; Sánchez-Chapado M; López JI; Ropero S
J Urol; 2016 Mar; 195(3):619-26. PubMed ID: 26551297
[TBL] [Abstract] [Full Text] [Related]
13. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract] [Full Text] [Related]
14. A small molecule inhibitor of etv1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
Rahim S; Minas T; Hong SH; Justvig S; Çelik H; Kont YS; Han J; Kallarakal AT; Kong Y; Rudek MA; Brown ML; Kallakury B; Toretsky JA; Üren A
PLoS One; 2014; 9(12):e114260. PubMed ID: 25479232
[TBL] [Abstract] [Full Text] [Related]
15. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.
Jarosek SL; Virnig BA; Chu H; Elliott SP
Eur Urol; 2015 Feb; 67(2):273-80. PubMed ID: 25217421
[TBL] [Abstract] [Full Text] [Related]
16. Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups.
Azelie C; Gauthier M; Mirjolet C; Cormier L; Martin E; Peignaux-Casasnovas K; Truc G; Chamois J; Maingon P; Créhange G
Radiat Oncol; 2012 Sep; 7():158. PubMed ID: 22978763
[TBL] [Abstract] [Full Text] [Related]
17. YK-4-279 inhibits ERG and etv1 mediated prostate cancer cell invasion.
Rahim S; Beauchamp EM; Kong Y; Brown ML; Toretsky JA; Üren A
PLoS One; 2011 Apr; 6(4):e19343. PubMed ID: 21559405
[TBL] [Abstract] [Full Text] [Related]
18. A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies.
Attard G; Rizzo S; Ledaki I; Clark J; Reid AH; Thompson A; Khoo V; de Bono JS; Cooper CS; Hudson DL
Prostate; 2009 Oct; 69(14):1507-20. PubMed ID: 19544327
[TBL] [Abstract] [Full Text] [Related]
19. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA
Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179
[TBL] [Abstract] [Full Text] [Related]
20. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract] [Full Text] [Related]
[Next]
